Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Silvia MarchianòMichele BiagioliMartina BordoniElva MorrettaCristina Di GiorgioValentina VelleccoRosalinda RoselliRachele BelliniCarmen MassaLuigi CariGinevra UrbaniPatrizia RicciMaria Chiara MontiAntonino GiordanoVincenzo BrancaleoneMariarosaria BucciAngela ZampellaEleonora DistruttiEnrico CieriGiuseppe CirinoStefano FiorucciPublished in: Journal of the American Heart Association (2023)
FXR and GPBAR1 maintain intestinal, liver, and cardiovascular homeostasis, and their therapeutic targeting with a dual GPBAR1/FXR ligand and atorvastatin holds potential in the treatment of liver and cardiovascular components of nonalcoholic fatty liver disease.